Shares of United Therapeutics Corp. (NASDAQ:UTHR) have been assigned a consensus recommendation of “Hold” from the twelve analysts that are covering the stock. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $146.75.

A number of brokerages recently commented on UTHR. Zacks Investment Research downgraded shares of United Therapeutics Corp. from a “buy” rating to a “hold” rating in a research note on Monday, August 1st. JPMorgan Chase & Co. reduced their price target on United Therapeutics Corp. from $145.00 to $129.00 and set a “neutral” rating on the stock in a research report on Friday, July 29th. Jefferies Group reaffirmed a “hold” rating and set a $120.00 price target on shares of United Therapeutics Corp. in a research report on Friday, July 29th. HC Wainwright reaffirmed a “hold” rating on shares of United Therapeutics Corp. in a research report on Friday, July 29th. Finally, Wedbush reaffirmed an “outperform” rating and set a $229.00 price target on shares of United Therapeutics Corp. in a research report on Thursday, July 28th.

In other United Therapeutics Corp. news, Director Christopher Patusky sold 5,000 shares of the company’s stock in a transaction on Thursday, September 1st. The shares were sold at an average price of $122.73, for a total value of $613,650.00. Following the sale, the director now directly owns 5,000 shares of the company’s stock, valued at $613,650. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,249 shares of the company’s stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $125.78, for a total transaction of $157,099.22. Following the completion of the sale, the chief executive officer now directly owns 1,389 shares in the company, valued at $174,708.42. The disclosure for this sale can be found here. Insiders own 7.50% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. GSA Capital Partners LLP raised its stake in United Therapeutics Corp. by 4.0% in the second quarter. GSA Capital Partners LLP now owns 32,696 shares of the biotechnology company’s stock valued at $3,463,000 after buying an additional 1,267 shares during the last quarter. Riverhead Capital Management LLC raised its stake in United Therapeutics Corp. by 134.2% in the first quarter. Riverhead Capital Management LLC now owns 60,875 shares of the biotechnology company’s stock valued at $6,783,000 after buying an additional 34,883 shares during the last quarter. UBS Asset Management Americas Inc. raised its stake in United Therapeutics Corp. by 7.3% in the first quarter. UBS Asset Management Americas Inc. now owns 226,285 shares of the biotechnology company’s stock valued at $25,215,000 after buying an additional 15,402 shares during the last quarter. Lazard Asset Management LLC raised its stake in United Therapeutics Corp. by 20.7% in the first quarter. Lazard Asset Management LLC now owns 234,718 shares of the biotechnology company’s stock valued at $26,153,000 after buying an additional 40,190 shares during the last quarter. Finally, State Street Corp raised its stake in United Therapeutics Corp. by 6.1% in the first quarter. State Street Corp now owns 1,846,710 shares of the biotechnology company’s stock valued at $205,778,000 after buying an additional 105,824 shares during the last quarter.

United Therapeutics Corp. (NASDAQ:UTHR) opened at 117.59 on Monday. United Therapeutics Corp. has a one year low of $97.52 and a one year high of $164.04. The company has a market capitalization of $5.11 billion, a PE ratio of 5.69 and a beta of 1.42. The company has a 50-day moving average price of $122.12 and a 200-day moving average price of $115.95.

United Therapeutics Corp. (NASDAQ:UTHR) last issued its quarterly earnings data on Thursday, July 28th. The biotechnology company reported $4.55 EPS for the quarter, topping analysts’ consensus estimates of $3.22 by $1.33. The company earned $412.60 million during the quarter, compared to the consensus estimate of $395.15 million. United Therapeutics Corp. had a net margin of 64.26% and a return on equity of 49.30%. United Therapeutics Corp.’s revenue for the quarter was up 18.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.55 earnings per share. Analysts expect that United Therapeutics Corp. will post $15.82 earnings per share for the current fiscal year.

About United Therapeutics Corp.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

5 Day Chart for NASDAQ:UTHR

Receive News & Stock Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related stocks with our FREE daily email newsletter.